CA2168091A1 - Croissance in vitro de precurseurs neutrophiles et de precurseurs de megacaryocytes dans un milieu exempt de serum - Google Patents
Croissance in vitro de precurseurs neutrophiles et de precurseurs de megacaryocytes dans un milieu exempt de serumInfo
- Publication number
- CA2168091A1 CA2168091A1 CA002168091A CA2168091A CA2168091A1 CA 2168091 A1 CA2168091 A1 CA 2168091A1 CA 002168091 A CA002168091 A CA 002168091A CA 2168091 A CA2168091 A CA 2168091A CA 2168091 A1 CA2168091 A1 CA 2168091A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- serum
- free
- megakaryocyte
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0644—Platelets; Megakaryocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/98—Xeno-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
On décrit des compositions de milieux exempts de sérum et de protéines animales, devant être utilisées conjointement avec des facteurs de croissance hématopoiétique pour la croissance in vitro de précurseurs de neutrophiles et de mégacaryocytes humains. Le milieu est composé d'un milieu de base, d'un corticostéroïde, de transferrine, d'insuline, de cholestérol, d'éthanolamine et d'albumine humaine. L'invention concerne également des procédés de préparation de suspensions, exemptes de sérum et de protéines, animales, de cellules précurseurs hématopoiétiques humaines, dans lesquelles le composant cellulaire comprend au moins 16 % environ de précurseurs de neutrophiles et au moins 1 % environ de précurseurs de mégacaryocytes. On décrit des suspensions exemptes de sérum et de protéines, animales, dans lesquelles le composant cellulaire comprend au moins 30 % environ, et de préférence plus de 60 % de précurseurs de neutrophiles. Les précurseurs de neutrophiles comprennent des cellules blastiques, des promyélocytes, des myélocytes neutrophiles et des métamyélocytes neutrophiles. On décrit également des suspensions de cellules exemptes de sérum et de protéines, animales, dans lesquelles le composant cellulaire comprend au moins 3 % environ et de préférence plus de 8 % de précurseurs de mégacaryocytes, ainsi que des suspensions de cellules exemptes de sérum et de protéines animales, dans lesquelles le composant cellulaire comprend des unités formant des colonies et des unités formant des grappes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11027793A | 1993-08-23 | 1993-08-23 | |
US08/110,277 | 1993-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2168091A1 true CA2168091A1 (fr) | 1995-03-02 |
Family
ID=22332160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002168091A Abandoned CA2168091A1 (fr) | 1993-08-23 | 1994-08-23 | Croissance in vitro de precurseurs neutrophiles et de precurseurs de megacaryocytes dans un milieu exempt de serum |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0719326A1 (fr) |
JP (1) | JPH09505462A (fr) |
AU (1) | AU702871B2 (fr) |
CA (1) | CA2168091A1 (fr) |
IL (1) | IL110755A (fr) |
SG (1) | SG52619A1 (fr) |
WO (1) | WO1995006112A1 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248319B1 (en) | 1989-10-16 | 2001-06-19 | Krisztina M. Zsebo | Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides |
US6207454B1 (en) | 1989-10-16 | 2001-03-27 | Amgen Inc. | Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide |
US6852313B1 (en) | 1989-10-16 | 2005-02-08 | Amgen Inc. | Method of stimulating growth of melanocyte cells by administering stem cell factor |
US7144731B2 (en) | 1989-10-16 | 2006-12-05 | Amgen Inc. | SCF antibody compositions and methods of using the same |
US9068164B1 (en) * | 1995-02-02 | 2015-06-30 | Tristem Trading (Cyprus) Limited | Method of preparing an undifferentiated cell |
AU6125396A (en) * | 1995-06-07 | 1996-12-30 | Novartis Ag | Serum-free media for primitive hematopoietic cells and metho ds of use thereof |
WO1997033978A1 (fr) * | 1996-03-12 | 1997-09-18 | Life Technologies, Inc. | Additif pour milieu de culture nutritif pour cellules hematopoietiques |
AU4330597A (en) | 1996-08-30 | 1998-03-19 | Life Technologies, Inc. | Serum-free mammalian cell culture medium, and uses thereof |
US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
US6811776B2 (en) | 2000-12-27 | 2004-11-02 | The Regents Of The University Of Michigan | Process for ex vivo formation of mammalian bone and uses thereof |
WO2005063968A1 (fr) * | 2003-12-26 | 2005-07-14 | Gs Platz Co Ltd | Milieu de base pour la culture de cellules es |
JP4651282B2 (ja) | 2004-01-21 | 2011-03-16 | 田辺三菱製薬株式会社 | 造血幹細胞及び造血前駆細胞の増幅方法 |
US7923013B2 (en) | 2004-12-28 | 2011-04-12 | The Rockefeller University | Glycolipids and analogues thereof as antigens for NKT cells |
CA2591232C (fr) | 2004-12-28 | 2014-10-21 | The Rockefeller University | Glycolipides et analogues associes utilises en tant qu'antigenes des lymphocytes nkt |
US7837990B2 (en) | 2005-03-28 | 2010-11-23 | The Rockefeller University | In vivo expanded NKT cells and methods of use thereof |
EP3424507A1 (fr) | 2006-03-24 | 2019-01-09 | Children's Medical Center Corporation | Procédé de modulation de croissance de cellules souches hématopoïétiques |
AU2015207905B2 (en) * | 2006-03-24 | 2017-04-27 | Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
AU2013202353B2 (en) * | 2006-03-24 | 2015-05-07 | Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
JP5426389B2 (ja) | 2006-10-20 | 2014-02-26 | チルドレンズ メディカル センター コーポレーション | 組織の再生を亢進するための方法 |
WO2010091052A2 (fr) | 2009-02-03 | 2010-08-12 | Children's Medical Center Corporation | Procédés de renforcement de greffe de cellule souche hématopoïétique/progénitrice |
US9056085B2 (en) | 2009-02-03 | 2015-06-16 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
EP2729560A4 (fr) * | 2011-07-06 | 2014-12-03 | Cellerant Therapeutics Inc | Cellules progénitrices mégacaryocytaires pour la production de plaquettes |
EP2785350B1 (fr) | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Méthodes améliorées permettant de traiter l'ischémie |
CN104066837B (zh) | 2011-12-02 | 2020-12-08 | 菲特治疗公司 | 增强的干细胞组合物 |
EP2882846B1 (fr) | 2012-06-05 | 2018-09-05 | The Regents of the University of California | Procédés et compositions pour la production rapide de cellules épithéliales pigmentées de la rétine à partir de cellules multipotentes |
EP2968416A4 (fr) | 2013-03-15 | 2016-08-17 | Fate Therapeutics Inc | Essai d'activité biologique de cellules pour un potentiel thérapeutique |
JP2021180620A (ja) * | 2020-05-18 | 2021-11-25 | 株式会社マイオリッジ | 目的細胞の生産方法、目的細胞による生産物の生産方法、および無血清培地 |
FR3128874A1 (fr) * | 2021-11-09 | 2023-05-12 | Crossject | Solution pharmaceutique d’hydrocortisone pour dispositif d’injection |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5004681B1 (en) * | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
WO1992006178A1 (fr) * | 1990-10-05 | 1992-04-16 | Systemix, Inc. | Croissance, production et composition des megacaryocytes et des plaquettes |
-
1994
- 1994-08-23 IL IL11075594A patent/IL110755A/xx not_active IP Right Cessation
- 1994-08-23 AU AU76744/94A patent/AU702871B2/en not_active Ceased
- 1994-08-23 SG SG1996006929A patent/SG52619A1/en unknown
- 1994-08-23 CA CA002168091A patent/CA2168091A1/fr not_active Abandoned
- 1994-08-23 WO PCT/US1994/009622 patent/WO1995006112A1/fr not_active Application Discontinuation
- 1994-08-23 EP EP94927235A patent/EP0719326A1/fr not_active Withdrawn
- 1994-08-23 JP JP7507759A patent/JPH09505462A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU702871B2 (en) | 1999-03-11 |
IL110755A0 (en) | 1994-11-11 |
WO1995006112A1 (fr) | 1995-03-02 |
JPH09505462A (ja) | 1997-06-03 |
SG52619A1 (en) | 1998-09-28 |
AU7674494A (en) | 1995-03-21 |
IL110755A (en) | 2000-11-21 |
EP0719326A1 (fr) | 1996-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6037174A (en) | Preparation of serum-free suspensions of human hematopoietic cells or precursor cells | |
AU702871B2 (en) | (In vitro) growth of neutrophil and megakaryocyte precursors in serum-free media | |
US6241984B1 (en) | Human hematopoietic progenitor cell preparations and their expansion in a liquid medium | |
Debili et al. | The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors | |
US5744361A (en) | Expansion of human hematopoietic progenitor cells in a liquid medium | |
Sitnicka et al. | The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells | |
Sandstrom et al. | Effects of CD34+ cell selection and perfusion on ex vivo expansion of peripheral blood mononuclear cells | |
US6733746B2 (en) | Hematopoietic cell culture nutrient supplement | |
US6667034B2 (en) | Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture, methods for assaying the effect of substances on lineage-specific cell production, and cell compositions produced by these cultures | |
Wada et al. | Expression of major blood group antigens on human erythroid cells in a two phase liquid culture system | |
WO1996040866A1 (fr) | Milieux sans serum pour des cellules hematopoietiques primaires et procedes d'utilisation | |
US5955357A (en) | In-vitro-derived human neutrophil precursor cells | |
Mazur et al. | Isolation of large numbers of enriched human megakaryocytes from liquid cultures of normal peripheral blood progenitor cells | |
JPH08509377A (ja) | ヒトのエリスロイド前駆細胞集団 | |
US5846529A (en) | Infusion of neutrophil precursors for treatment of neutropenia | |
US5888499A (en) | Method for increasing neutrophil populations using in vitro-derived human neutrophil precursor cells | |
Smith et al. | Neutrophil maturation of CD34+ cells from peripheral blood and bone marrow in serum-free culture medium with PIXY321 and granulocyte-colony stimulating factor (G-CSF) | |
Hirao et al. | Synergism of interleukin 12, interleukin 3 and serum factor on primitive human hematopoietic progenitor cells | |
Cohen et al. | Ex Vivo Expanded (EVE) Megakaryocytes (MK) for Supportive Care of Patients with Breast Cancer Hematologic Malignancies: A Phase I/II Clinical Study | |
WO1999000486A1 (fr) | Compositions et procedes permettant d'induire la croissance et la differenciation de cellules souches hematopietiques | |
EP0675726A1 (fr) | Croissance, production et composition des megacaryocytes et des thrombocytes | |
Zandstra | Cytokine-dependent regulation of human hematopoietic cell self-renewal and differentiation in suspension cultures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |